Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print April 25, 2007, doi:10.1212/01.wnl.0000264004.62612.44)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
01.wnl.0000264004.62612.44v1
70/3/185    most recent
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Shi, J.
Right arrow Articles by Kuniyoshi, S. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shi, J.
Right arrow Articles by Kuniyoshi, S. M.
Related Collections
Right arrow All Clinical Neurology
Right arrow All Cognitive Disorders/Dementia
Right arrow All Demyelinating disease (CNS)
Right arrow All Genetics
NEUROLOGY 2008;70:185-190
© 2008 American Academy of Neurology

APOE {varepsilon}4 allele is associated with cognitive impairment in patients with multiple sclerosis

J. Shi, MD, PhD, C. B. Zhao, MD, PhD, T. L. Vollmer, MD, T. M. Tyry, PhD and S. M. Kuniyoshi, MD, PhD

From the Division of Neurology (J.S., C.B.Z., T.L.V., T.M.T.), Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ; and Department of Neurology (S.M.K.), University of Texas Medical Branch, Galveston.

Address correspondence and reprint requests to Dr. Jiong Shi, Barrow Neurological Institute, 500 W. Thomas Road, Suite 720, Phoenix, AZ 85013 jiong.shi{at}chw.edu

Background: The role of apolipoprotein E (APOE) polymorphism has been well recognized in other cognitive neurodegenerative disorders, such as Alzheimer disease. Its role in multiple sclerosis (MS) is less clear, though studies indicate that 40% to 60% of patients with MS have evidence of cognitive impairment.

Objective: To determine whether there is an association between APOE {varepsilon}4 and cognitive deficits in MS.

Methods: We performed a standardized battery of neuropsychological tests investigating the four cognitive domains commonly impaired in MS and assessed the association of the presence of APOE {varepsilon}4 with cognition in MS.

Results: A strong association was found between the presence of APOE {varepsilon}4 and cognitive deficits in patients with MS, particularly in the domains of learning and memory. This association was strongest in our youngest cohort (age 31 to 40) of patients with MS.

Conclusions: APOE {varepsilon}4 is significantly associated with cognitive impairment in patients with multiple sclerosis (MS). However, the modest effects do not justify APOE genotyping of patients with MS in clinical practice.

Editorial, page 164

e-Pub ahead of print on April 25, 2007, at www.neurology.org.

Supported by a Pilot Research Award from the National Multiple Sclerosis Society.

Disclosure: The authors report no conflicts of interest.

Received January 17, 2007. Accepted in final form March 6, 2007.




This article has been cited by other articles:


Home page
 NeuroscientistHome page
Disease Mechanisms in Neuroscience
Neuroscientist, June 1, 2008; 14(3): 234 - 234.
[PDF]

Correspondence:

Read all Correspondence

APOE 4 allele is associated with cognitive impairment in patients with multiple sclerosis
Alan A. Mazurek
Neurology Online, 13 Mar 2008 [Full text]
Reply from the authors
Jiong Shi
Neurology Online, 13 Mar 2008 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by AAN Enterprises, Inc.